Skip to main content
Clinical Trials/DRKS00000319
DRKS00000319
Completed
未知

Prostagen Study - Investigation of polymorphisms in genes of the fatty acid metabolism in relation to the evolvement and further development of prostate cancer

Klinik für Tumorbiologie0 sites158 target enrollmentStarted: February 1, 2010Last updated:

Overview

Phase
未知
Status
Completed
Sponsor
Klinik für Tumorbiologie
Enrollment
158

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomized controlled study
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to one (—)
Sex
Male

Inclusion Criteria

  • Patient inclusion criteria:
  • \- Patients with histologically proven prostate cancer who are treated or advised in one of the centers involved in the study
  • \- Written informed consent
  • Inclusion criteria for healthy subjects:
  • \- Subjects without prostate cancer or any other tumor, which are screened in one of the study centers and are 70 years or older.
  • \- Exclusion of prostate cancer according to one of the following criteria:
  • \* Men with a PSA level of maximum 10 ng/ml, who underwent a 12x punch biopsy with a negative result.
  • \* Men with benign prostatic hyperplasia (BPH), in whom a transurethral resection of the prostate (TUR\-P) was conducted and the histology of the recovered material was negative (PSA maximum 10 ng /l).
  • \* PSA less than 4ng/l and no prostate cancer family history
  • \- Written informed consent

Exclusion Criteria

  • \- Patients / healthy subjects with a known allergy to seafood
  • \- Patients / healthy subjects who can not eat or are on a special diet
  • \- Patients / healthy subjects with malabsorption (i.e. after gastrointestinal surgery, inflammatory bowel disease)
  • \- Patients / healthy subjects with severe internal diseases, especially with impaired coagulation, liver or gall bladder disease, bile duct tumors, or pancreatitis
  • \- Patients / healthy subjects who are already taking omega\-3 fatty acids supplementation or other dietary supplements and drugs that are likely to affect the results of the research
  • \- Patients / healths subjects with psychiatric or CNS disorders, who are not able to consent to participation in the study

Investigators

Sponsor
Klinik für Tumorbiologie

Similar Trials